Varespladib

A phospholipase A2 inhibitor

Varespladib
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Varespladib is a small-molecule inhibitor of secretory phospholipase A2 (sPLA2), an enzyme involved in the inflammatory process and the production of pro-inflammatory lipid mediators. It has been investigated for its potential therapeutic effects in various inflammatory conditions and cardiovascular diseases.

Mechanism of action

Varespladib functions by inhibiting the activity of sPLA2, which is responsible for the hydrolysis of phospholipids, leading to the release of arachidonic acid. Arachidonic acid is a precursor for the synthesis of eicosanoids, which are potent mediators of inflammation. By blocking sPLA2, varespladib reduces the production of these inflammatory mediators.

Clinical research

Varespladib has been studied in clinical trials for its potential to reduce inflammation and improve outcomes in patients with acute coronary syndrome (ACS). However, results from these studies have been mixed, with some trials showing no significant benefit in reducing cardiovascular events.

In addition to cardiovascular research, varespladib has been explored as a treatment for snakebite envenomation. The inhibition of sPLA2 is thought to counteract the toxic effects of certain snake venoms, which often contain sPLA2 enzymes.

Chemical properties

Varespladib is available in different forms, including varespladib methyl and varespladib sodium. These forms differ in their chemical structure and solubility, which can affect their pharmacokinetic properties and clinical applications.

Related pages

• Phospholipase A2
• Eicosanoid
• Inflammation
• Acute coronary syndrome